HOME > TOP STORIES
TOP STORIES
-
BUSINESS Axcelead’s Next CEO Eyes Sales of 120 Billion Yen, Ramp-Up in Mega Pharma Orders
June 21, 2024
-
BUSINESS SanBio Says Its Lead Cell Therapy Could Be Shipped from 2025 If All Goes Well
June 21, 2024
-
BUSINESS Gilead Eager to See More Authorized CAR-T Treatment Centers in Japan
June 21, 2024
-
BUSINESS Tsumura Looks to Plant “Guidepost” for Development of Botanical Drugs in US
June 20, 2024
-
REGULATORY SanBio’s Lead Cell Therapy in Line for Conditional Nod but Can’t Be Shipped Until Comparability Is Confirmed
June 20, 2024
-
BUSINESS Concerns Grow over Supply of Cephem Antibiotics after Choseido Plant Halt
June 19, 2024
-
REGULATORY LDP Tweaks Honebuto Text on Off-Year Revision, Waters Down Push for CEA Expansion
June 18, 2024
-
BUSINESS Kunio Takeda, Former CEO of Takeda Pharmaceutical, Dies at 84
June 18, 2024
-
BUSINESS India’s Biocon to Set Up Japan Office to Make Full Inroads into Generic API Sector
June 18, 2024
-
ORGANIZATION FPMAJ Hails 2024 Reform, but Frets No Mention of Scrapping Off-Year Cuts in Honebuto Draft
June 17, 2024
-
ACADEMIA MHLW-Funded Study Group Designing New Care Delivery Model for Alzheimer’s
June 14, 2024
-
BUSINESS Lilly Set to Raise Profile as Only Eczema Player with Oral and Injectable Options
June 13, 2024
-
REGULATORY Honebuto Draft Equivocal on Off-Year Price Cuts, but Focuses on FY2025 Revision
June 12, 2024
-
ACADEMIA Akira Endo, Who Pioneered Discovery of Statins, Dies at 90
June 12, 2024
-
REGULATORY MHLW to Issue Nitrosamine Risk Communication Guidance by June-End; Draft Now Ready
June 11, 2024
-
COMMENTARY Industry’s Ability to Communicate Being Put to Test as Views on Off-Year Price Cuts Change
June 11, 2024
-
BUSINESS Susana Murteira Tapped as Amgen Japan President
June 11, 2024
-
REGULATORY Japan Eyes Withdrawal Rule for Conditional Approval, More Flexible Nods
June 10, 2024
-
REGULATORY LDP Policy Board Endorses Fiscal Consolidation HQ’s Proposal to Extend CEAs
June 10, 2024
-
COMMENTARY With Only 5 Months Until Nitrosamine Self-Inspection Deadline, Many Challenges Remain
June 7, 2024
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
